Observational study of outpatients with schizophrenia in the Middle East and Africa - 3- and 6-month efficacy and safety results: The Intercontinental Schizophrenia Outpatient Health Outcomes Study

South African Journal of Psychiatry

Volumn 11, Issue 1, 2005, Pages 16-24

  Treuer, Tamas ^a   Dossenbach, Martin ^a   Bitter, Istvan ^a   Birsöz, Sunar ^b   Belaid, Abderrahmane ^c   Akram, Aly ^d   El Fiki, Mohammed R ^e  

^a Eli Lilly Regional Operations   (Austria)

^b AKDENIZ UNIVERSITY   (Turkey)

^c Etablissement Hospitalo Universitaire Spécialisé de Psychiatrie Mahfoud BOUCEBCI   (Algeria)

^d Suliman Faqueeh Hospital   (Saudi Arabia)

^e AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SULPIRIDE; THIORIDAZINE; TRIFLUOPERAZINE; ZUCLOPENTHIXOL;

ADULT; AFRICA; ARTICLE; BODY WEIGHT; CLINICAL OBSERVATION; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; IMPOTENCE; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; MIDDLE EAST; OUTCOMES RESEARCH; OUTPATIENT CARE; PROSPECTIVE STUDY; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SIDE EFFECT; TARDIVE DYSKINESIA; WEIGHT GAIN;

EID: 20044390056     PISSN: 16089685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Thornly B, Adams C. Content and quality of 2000 controlled trials in schizophrenia over 50 years. BMJ 1998; 317: 1181-1184.
2. Tsuang MT. Observational studies versus experimental studies would the results be similar? Editorial comment. Psychosom Med 1999; 61: 146-147.
3. Albright PS, Livingstone S, Keegan DL, Ingham M, Shrikhande S, Le Lorier J. Reduction of healthcare resource utilisation and costs following the use of risperidone for patients with schizophrenia previously treated with standard antipsychotic therapy. Clinical Drug Investigation, 1996; 11: 289-299
4. Hamilton SH, Revicki DA, Edgell ET, Genduso LA, Tollefson G. Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Pharmacoeconomics 1999; 15: 469-480.
5. Tollefson GD, Beasley CM, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997; 154: 457-465.
6. Beasley CM,jun. Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S. Olanzapine versus placebo and haloperidol. Acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996; 14: 111-123.
7. Beasley CM, jun. Dellva MA, Tamura RN, et al. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Br J Psychiatry 1999; 174: 23-30.
8. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993; 13: 25-40.
9. Janicak PG, Keck PE jun. Davis JM, et al. A double-blind, randomized, prospective evaluation of the efficacy and safety of risperidone versus haloperidol in the treatment of schizoaffective disorder. J Clin Psychopharmacol 2001; 21: 360-368.
10. Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997; 17: 407-418.
11. Carrasco JL, Gutierrez M, Gomez JC, et al. Treatment of severely psychotic inpatients with schizophrenia: olanzapine versus other antipsychotic drugs. Int Clin Psychopharmacol 2002; 17: 287-295.
12. Gomez JC, Sacristan JA, Hernandez J, et al. The safety of olanzapine compared with other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO Study). Pharmacoepidemiologic Study of Olanzapine in Schizophrenia. J Clin Psychiatry 2000; 61: 335-343.
13. Sacristan JA, Gomez JC, Monlejo AL, Vieta E, Gregor KJ. Doses of olanzapine, risperidone, and haloperidol used in clinical practice results of a prospective pharmacoepidemiologic study, EFESO Study Group. Estudio Farmacoepidemiologico en la Esquizofrenia con Olonzapina. Clin Ther 2000; 22: 583-599.
14. Kasper S, Rosillon D, Duchesne I; RODOS Investigator Group. Risperidone olanzopine drug outcomes studies in schizophrenia (RODOS): efficacy and tolerability results of an international naturalistic study. Int Clin Psychopharmacol 2001; 16(4): 179-187.
15. Garcia-Cabeza I, Gomez JC, Sacristan JA, Edgell E, Gonzalez De Chavez M. Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study). Bio Med Central Psychiatry 2001; 1(1):7.
16. Knapp M, Chisholm D, Leese M, et al. T. Comparing patterns and costs of schizophrenia care in five European countries: the EPSILON study. European Psychiatric Services: Inputs Linked to Outcome Domains and Needs. Acta Psychiatr Scand 2002; 105(1):42-54.
17. Korb F, Yenilmez C, Belaid A, Ghazi M, Omar A, Bitter I.: The Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) Study. Baseline clinical and functional characteristics and antipsychotic use patterns in the North Africa and Middle East region. South African Psychiatric Review (in press).
18. Sernyak, MJ, Leslie, D, Rosenheck, R. Use of system-wide outcomes monitoring data to compare the effectiveness of atypical neuroleptic medications. Am J Psychiatry 2003; 160: 310-315.
19. Kasper S, Jones M, Duchesne I; RODOS Investigator Group. Risperidone olanzapine drug outcomes studies in schizophrenic (RODOS): health economic results of an international naturalistic study. Int Clin Psychopharmacol 2001; 16: 189-196.
20. Alvarez E, Bobes J, Gomez JC, et al; EUROPA Study Group. Safety of olanzapine versus conventional antipsychotics in the treatment of patients with acute schizophrenia. A naturalistic study. Eur Neuropsychopharmacol 2003; 13(1): 39-48.
21. Kinon B, Stauffer V, Wang L, Thi K, Kollack-Walker S. Olanzapine improves tardive dyskinesia in patients with schizophrenia in a controlled prospective study. Eur Neuropsychopharmacol 2002; 12: (suppl 3), S255-S256.
22. Compton MT, Miller AH. Antipsychotic-induced hyperprolactinemia and sexual dysfunction. Psychopharmacol Bull 2002; 36(1): 143-164.
23. Cutler AJ. Sexual dysfunction and antipsychotic treatment. Psychoneuroendocrinology 2003; 28: Suppl 1, 69-82.
24. Basson BR, Kinon BJ, Taylor CC, Szymanski KA, Gilmore JA, Tollefson GD. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry 2001; 62: 231-238.
25. Kinon BJ, Basson BR, Gilmore JA, Tollefson GD. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 2001; 62: 92-100.